Treats serious infections caused by susceptible strains of the designated microorganisms…. ANDA 65072, held by Hikma Pharmaceuticals. Cefotaxime Sodium.
As of Nov 21, 2026, ANDA 65072 (Cefotaxime), held by Hikma Pharmaceuticals, was first approved by FDA on Nov 20, 2002, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Treatment Cefotaxime for Injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes* (Group A streptococci) and other streptococci (excluding enterococci, e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2002 | Original application | Approved |
| CefotaximeEQ 500MG BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| CefotaximeEQ 1GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| CefotaximeEQ 2GM BASE/VIAL · injectable;injection | Cefotaxime Sodium | Discontinued |
| Jun 4, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 4, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Supplement 11Labeling | Approved | None posted |
| Nov 20, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters